Kristl G. Claeys
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications
Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.
Journal: Expert opinion on biological therapy
Published: September 01, 2026
Quantifying Disease Progression in Patients With Charcot-Marie-Tooth Neuropathy Type 1A Using Quantitative Muscle MRI and Clinical Outcomes.
Journal: Neurology
Published: August 05, 2026
Natural History of Adult-Onset Myotonic Dystrophy Type 1: Longitudinal Changes in Radiologic, Clinical, and Patient-Reported Outcomes.
Journal: Neurology
Published: July 29, 2026
Gastrointestinal manifestations are common and highly burdensome in patients with adult-onset myotonic dystrophy type 1.
Journal: Neuromuscular disorders : NMD
Published: May 28, 2026
Change in respiratory outcomes in adults with Duchenne muscular dystrophy in the era of corticosteroids.
Journal: Journal of neuromuscular diseases
Published: May 13, 2026
3D Radiomic Texture Analysis of Quantitative Muscle MRI Enhances the Distinction Between Myotonic Dystrophy Type 1 and Charcot-Marie-Tooth Neuropathy Type 1A: A Proof-of-Concept Study.
Journal: European journal of neurology
Published: May 03, 2026
Burden of illness of Duchenne muscular dystrophy in Belgium: A retrospective, descriptive, cross-sectional study.
Journal: Journal of neuromuscular diseases
Published: March 14, 2026
Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis.
Journal: Journal of neuroimmunology
Published: February 25, 2026
Upper limb freezing, palilalia and tachyphemia in atypical Pantothenate kinase-associated neurodegeneration.
Journal: Parkinsonism & related disorders
Published: December 18, 2025
Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.
Journal: Annals of clinical and translational neurology
Published: November 21, 2025
Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study.
Journal: Neuromuscular disorders : NMD
Published: September 05, 2025
Transition from childhood to adulthood in neuromuscular disorders: results from the ERN EURO-NMD survey.
Journal: Orphanet journal of rare diseases
Published: August 26, 2025
Last Updated: 09/26/2026